Modelling the Epidemiology of Infectious Diseases for Decision Analysis

Neumann PJ, Fang C-H, Cohen JT. 30 years of pharmaceutical cost-utility analyses. growth, diversity and methodological improvement. Pharmacoeconomics 2009; 27 (10): 861–72 WHO. WHO global burden of disease: 2004 update [online]. Available from URL: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html [Accessed 2010 Apr 17] Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11 (4 Suppl.): S5–11 World Bank. World development report 1993: investing in health. Oxford: Oxford University Press, 1993 GAVI Alliance [online]. Available from URL: http://www.gavialliance.org [Accessed 2011 Jan 18] Mitchell M, Walker D, Zuber P, et al. Evidenced-based decision making about Hib vaccination. Lancet 2005; 365 (9463): 936–7 Grassly NC, Fraser C. Mathematical models of infectious disease transmission. Nat Rev Microbiol 2008; 6 (6): 477–87 Roberts TE, Robinson S, Barton P, et al. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Transm Infect 2006; 82 (3): 193–200 Anonychuk AM, Tricco AC, Bauch CT, et al. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008; 26 (1): 17–32 Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74 Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38 Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics 2010; 28 (6): 449–61 Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26 Suppl. 10: K76–86 Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12 (5-6): 343–51 Hutubessy RC, Bendib LM, Evans DB. Critical issues in the economic evaluation of interventions against communicable diseases. Acta Trop 2001; 78 (3): 191–206 Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9 (8): 681–98 Welte R, Leidl R, Greiner W, et al. Health economics of infectious diseases. In: Kramer A, Kretzschmar M, Krickeberg K, editors. Modern infectious disease epidemiology: concepts, methods, mathematical models and public health. New York: Springer-Verlag, 2010 Beutels P, Van Doorslaer E, Van Damme P, et al. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003; 2 (5): 649–60 Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15 (12): 1295–310 Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191–215 Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373 (9657): 48–57 Glass RJ, Glass LM, Beyeler WE, et al. Targeted social distancing design for pandemic influenza. Emerg Infect Dis 2006; 12 (11): 1671–81 Gojovic MZ, Sander B, Fisman D. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009; 181: 673–80 Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5 (3): e74 Zagheni E, Billari FC, Manfredi P, et al. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008; 168 (9): 1082–90 Cooper BS, Medley GF, Stone SP, et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci USA 2004; 101 (27): 10223–8 Kelso JK, Milne GJ, Kelly H. Simulation suggests that rapid activation of social distancing can arrest epidemic development due to a novel strain of influenza. BMC Public Health 2009; 9: 117 Baggaley RF, Boily MC, White RG, et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20 (6): 805–12 Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Management 2001; 42 (2): 183–206 Wu JT, Leung GM, Lipsitch M, et al. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009; 6 (5): e1000085 Keeling MJ. Models of foot-and-mouth disease. Proc Biol Sci 2005; 272 (1569): 1195–202 Truscott J, Garske T, Chis-Ster I, et al. Control of a highly pathogenic H5N1 avian influenza outbreak in the GB poultry flock. Proc R Soc B 2007; 274 (1623): 2287–95 Fox JP, Elveback L, Scott W, et al. Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 1971; 94 (3): 179–89 Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397–409 Anderson RM, May RM. Vaccination against rubella andmeasles: quantitative investigations of different policies. J Hyg (Lond) 1983; 90 (2): 259–325 Ziv E, Daley CL, Blower SM. Early therapy for latent tuberculosis infection. Am J Epidemiol 2001; 153 (4): 381–5 Hens N, Ayele GM, Goeyvaerts N, et al. Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight European countries. BMC Infect Dis 2009; 9: 187 Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 1997; 94 (12): 6571–6 Melegaro A, Choi YH, George R, et al. Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect Dis 2010; 1090 Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8 (7): 851–61 Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 21 (1): 76–82 Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319: 1462–7 Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ 2010 May; 19 (5): 518–31 Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769 Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002–2006). Vaccine 2007; 25 (8): 1355–67 Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27 (4): 281–97 Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among olderadults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294 (16): 2043–51 Centers for Disease Control Prevention. Delayed onset and diminished magnitude of rotavirus activity: United States,November 2007–May 2008. MMWR Morb Mortal Wkly Rep 2008; 57 (June 25): 697–700 Shim E, Galvani AP. Impact of transmission dynamics onthe cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27 (30): 4025–30 Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004; 22 (31-32): 4203–14 De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 (2): 177–81 Edmunds WJ, Brisson M, Melegaro A, et al. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 2002; 20 (9-10): 1316–30 Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352 (6): 570–85 Kaye P, Malkani R, Martin S, et al. Invasive pneumococcal disease (IPD) in England and Wales after 7-valent conjugate vaccine (PCV7): potential impact of 10 and 13-valent vaccines [abstract]. 27th Annual Meeting of the European Society of Paediatric Infectious Diseases; 2008 June 9–13; Brussels [online]. Available from URL: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1245581527892 [Accessed 2010 Apr 17] Bauch CT, Anonychuk AM, Van Effelterre T, et al. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009; 29: 557–69 Kramer A, Akmatov M, Kretzschmar M. Principles of infectious disease epidemiology. In: Kramer A, Krickeberg K, Kretschmar M, editors. Modern infectious disease epidemiology: concepts, methods, mathematical models, and public health. New York: Springer Science and Business Media, 2010 Baguelin M, van Hoek AJ, Jit M, et al. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 2010; 28: 2370–84 Garnett GP, Kim JJ, French K, et al. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 Suppl. 3: S3–178–S3/186 Briggs A, Sculpher M, Buxton M. Uncertainty in the economicevaluation of health care technologies: the role ofsensitivity analysis. Health Econ 1994; 3 (2): 95–104 Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434–46 Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479–500 Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. Epub 2009 Jan 9 Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14 (4): 339–47 Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg 1985; 94: 365–436 Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5: 381–91 Zagheni E, Billari FC, Manfredi P. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008; 168 (9): 1082–90 Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20 (19-20): 2500–7 International Society for Pharmacoeconomics and Outcome Research. Pharmacoeconomic guidelines around the world [online]. Available from URL: http://www.ispor.org/peguidelines/index.asp [Accessed 2010 Apr 17] Nolan TM. The Australian model of immunization advice and vaccine funding. Vaccine 2010; 28S: A76–83 Walker DG, Hutubessy R, Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010; 28 (11): 2356–9 Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27 (44): 6121–8 Rozenbaum MH, van Hoek AJ, Vegter S, et al. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 2008; 7 (6): 753–82 Beutels P, Schuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8 (11): 727–33 Keogh-Brown MR, Smith RD, Edmunds JW, et al. The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and the Netherlands. Eur J Health Econ 2010 Dec; 11 (6): 543–54 Lamontagne E, Haacker M, Ventelou B, et al. Macroeconomic impact of HIV: the need for better modelling. Curr Opin HIV AIDS 2010; 5 (3): 249–54